Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vitamin D,Calcium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioAdaptives, Inc. Commences Development of a New Supplement for Womens Health
Details : PluriPain-PMS, an advanced, all natural anti-inflammatory and mood-enhancing Women’s Health formula to combat specific symptoms associated with the menstrual cycle.
Product Name : PluriPain-PMS
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : Vitamin D,Calcium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA
Details : Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in Company's Europ...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
November 27, 2022
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Updated Results From Clinical Trial With Diamyd® Presented Today At Diabetes Conference
Details : The diabetes vaccine Diamyd® (GAD-alum) is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical tria...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
September 20, 2022
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promising Topline Results for Intralymphatic Diamyd® in Patients With LADA
Details : Primary endpoints of safety and tolerability were met in Phase II clinical trial GADinLADA, in which diabetes vaccine Diamyd (GAD-alum) was administered directly into lymph node of 14 patients aged 30 to 70 years with autoimmune form of diabetes called L...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Pauses Start of DIAGNODE-3 In the US Pending Clarification on Study Drug
Details : The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The Phase III trial DIAGNODE-3, with a planned start date later during 2021 and primary completion end of 2025.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical AB Fully Recruited Patients in Clinical Trial with Diamyd®
Details : The clinical Phase II trial GADinLADA, where the diabetes vaccine Diamyd® is administered directly into the lymph node in patients with the autoimmune form of diabetes LADA, is fully recruited, and the first results from the trial are planned to be anno...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
September 04, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd® Phase IIb trial results published in Diabetes Care
Details : The patients, diagnosed with type 1 diabetes, have been given the diabetes vaccine Diamyd® directly into the lymph node on three occasions, one month apart, in combination with oral vitamin D (or its placebo) during four months, starting 30 days prior t...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
May 21, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : All 50 patients who participated in the extension of Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd® have now made their 24-month visit, and data will be presented in early July.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Update on the Design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd®
Details : The trial is designed to confirm the effect and safety of Diamyd® in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
April 03, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical To Present at Upcoming Scientific Conferences
Details : Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable